Sie verlassen Lundbeck Deutschland
Sie verlassen jetzt lundbeck.com/de. Bitte beachten Sie, dass die Informationen auf der Seite, auf die Sie verlinkt werden, möglicherweise nicht in vollem Umfang mit den gesetzlichen Bestimmungen in Deutschland, sowie die produktbezogenen Informationen mit den entsprechenden deutschen Fachinformationen für Arzneimittel übereinstimmen. Alle Informationen sollten mit Ihrem Arzt besprochen werden und ersetzen nicht die Beratung und Behandlung durch Ihren Arzt.
Financials
Key Facts, Figures, and Highlights of Lundbeck’s Financials
An overview of Lundbeck’s financial performance.
Financial Overview
| Income statement (DKKm) | 2023 | 2022 | 2021 | 2020 | 2019 |
| Revenue | 19,912 | 18,246 | 16,299 | 17,672 | 17,036 |
| Research and development costs | 3,457 | 3,754 | 3,823 | 4,545 | 3,116 |
| Operating profit before depreciation and amortization (EBITDA) | 5,207 | 4,663 | 3,720 | 4,783 | 4,823 |
| Profit/(loss) from operations (EBIT) | 3,195 | 2,852 | 2,010 | 1,990 | 3,153 |
| Net financials | 202 | 378 | 429 | 84 | 127 |
| Profit/(loss) before tax | 2,993 | 2,474 | 1,581 | 1,906 | 3,026 |
| Profit/(loss) for the year | 2.290 | 1,916 | 1,318 | 1,581 | 2,313 |
| Assets (DKKm) | 2023 | 2022 | 2021 | 2020 | 2019 |
| Non-current assets |
24,118 | 26,040 | 26,041 | 25,924 | 29,095 |
| Inventories |
4,427 | 4,046 | 2,775 | 2,163 | 2,204 |
| Receivables | 3,852 | 3,818 | 3,558 | 4,018 | 3,822 |
| Cash, bank balances and securities | 5,010 | 3,548 | 2,279 | 3,924 | 3,012 |
| Total assets | 37,407 | 37,452 | 34,653 | 36,029 | 38,133 |
| Equity and liabilities (DKKm) | 2023 | 2022 | 2021 | 2020 | 20191 |
| Equity |
22,045 | 20,779 | 18,279 | 16,973 | 16,782 |
| Non-current liabilities |
7,372 | 8,474 | 7,556 | 9,044 | 11,071 |
| Current liabilities | 7,990 | 8,199 | 8,818 | 10,012 | 10,280 |
| Total equity and liabilities | 37,407 | 37,452 | 34,653 | 36,029 | 38,133 |
| statement of Cash flows (DKKm) | 2023 | 2022 | 2021 | 2020 | 2019 |
| Cash flows from operating activities |
4,080 | 3,519 | 2,272 | 3,837 | 2,609 |
| Cash flows from investing activities | -498 | -1,892 | -610 | -467 | -7,755 |
| Cash flows from operating and investing activities (free cash flow) | 3,582 | 1,627 | 1,662 | 3,370 | -5,146 |
| Cash flows from financing activities | -2,085 | -387 | -3,336 | -2,394 | 4,548 |
| Interest-bearing debt, cash, bank balances and securities, net, year-end - net cash/(net debt) | 711 | -2,183 | -3,189 | -4,106 | -6,566 |
1) 2018-2019 have been restated to reflect the reversal of an impairment loss on the Rexulti® product rights in 2017.
2) In 2020 and 2021, securites amounted to DKK 0.
| Key figures | 2023 | 2022 | 2021 | 2020 | 20191 |
| EBIT margin (%) |
16.0 | 15.6 | 12.3 | 11.3 | 18.5 |
| Research and development ratio (%) | 17.4 | 20.6 | 23.5 | 25.7 | 18.3 |
| Return on equity (%) | 10.7 | 9.8 | 7.5 | 9.4 | 13.8 |
| Equity ratio (%) | 58.9 | 55.5 | 52.7 | 47.1 | 44.0 |
| Invested capital (DKKm) | 21,334 | 22,962 | 21,468 | 21,079 | 23,348 |
| Net debt/EBITDA | -0.1 | 0.5 | 0.9 | 0.9 | 1.4 |
| Effective tax rate (%) | 23.5 | 22.6 | 16.6 | 17.0 | 23.6 |
| Purchase of intangible assets, gross (DKKm) | 224 | 449 | 202 | 114 | 88 |
| Purchase of property, plant and equipment, gross (DKKm) | 277 | 371 | 410 | 364 | 356 |
| Purchase of financial assets, gross (DKKm) | - | - | - | 17 | 18 |
| Average number of employees | 5,566 | 5,399 | 5,488 | 5,717 | 5,475 |
| Share data | 2023 | 2022 | 2021 | 2020 | 2019 |
| Number of shares for the calculation of EPS (millions) | 999.2 | 992.9 | 993.3 |
993.7 |
993.5 |
| Earnings per share, basic (EPS) (DKK) | 2.31 | 1.93 | 1.33 |
1.59 |
2.33 |
| Earnings per share, diluted (DEPS) (DKK) | 2.31 | 1.93 | 1.33 |
1.59 |
2.33 |
| Proposed dividend per share (DKK) | 0.70 | 0.58 | 0.40 |
0.50 |
0.82 |
| Cash flow from operating activities per share, diluted (DKK) | 4.11 | 3.54 | 2.29 |
3.86 |
2.63 |
| Net asset value per share, diluted (DKK) | 22.22 | 20.93 | 18.40 |
17.08 |
16.89 |
| Market capitalization (DKKm) | 31,812 | 25,507 | 33.626 | 41,582 | 50,660 |
1) 2018-2019 have been restated to reflect the reversal of an impairment loss on the Rexulti® product rights in 2017.
More from Lundbeck
Investor Relations
Detailed information related to Lundbeck’s financial performance. Contact Palle Olesen, VP Investor Relations. + 45 3083 2426
The Share
A complete overview of our share data, shareholders,
dividends, and analyst coverage.
Reports and Presentations
Investor Reports, Presentations, Roadshows, Teleconferences, and Webcasts.